CVRx (CVRX) Stock Forecast & Price Target

CVRx Inc. is exhibiting a positive outlook due to a notable increase in the approval rates for Medicare Advantage prior authorizations, which rose to 50% in early 2026 from 44% in 2025. Additionally, the company has experienced growth in active implanting centers in the U.S., increasing to 252, as well as a strong Q4 performance with European revenue reaching $1.1 million, reflecting an 8% year-over-year increase. Furthermore, the company's revenue and gross margins in Q1 2026 exceeded fiscal year 2026 guidance midpoint, with year-over-year revenue growth of 14.5% and gross margins of 85%, indicating a strong start to the year and confidence in sustained growth throughout 2026.

CVRx Inc. faces significant financial challenges as it has consistently incurred substantial net losses since its inception, with expectations of continued losses in the foreseeable future, contributing to a negative outlook. The company's active accounts in the U.S. market have also decreased, ending the most recent quarter with 257 active centers, slightly below projected estimates, which may hinder revenue growth. Additionally, concerns regarding the potential negative perception of morbidity and mortality data could adversely affect the adoption of its Barostim neo device, despite existing clinical data and FDA approval.